Weight Management

Weight Management research, in depth

This category has seen more clinical translation than any other in the database. GLP-1 receptor agonists moved from research into approved medicine, and the next generation of metabolic compounds is being studied now.

From incretin biology to approved drugs

The breakthrough in this area came from incretin hormones — gut signals that influence appetite, gastric emptying and glucose control. GLP-1 receptor agonists such as Semaglutide reproduce that signalling, and Tirzepatide adds a second target, the GIP receptor. Both have completed large Phase 3 trial programs and reached regulatory approval for metabolic conditions, which is why their published evidence base is unusually strong for this site.

Research has not stopped there. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, is in active trials, and fragment-based compounds such as AOD-9604 are studied for fat metabolism through separate pathways entirely.

Where the research stands

This category is best read as a spectrum. At one end, the approved incretin agonists have mature, large-scale trial data — their published weight-change and cardiovascular figures come from tens of thousands of participants. At the other end sit investigational triple agonists and growth-hormone fragments whose evidence is far younger. The single most common mistake is assuming a compound is well-established simply because a category neighbour is; the gap between Semaglutide's evidence base and that of a fragment peptide is large.

It is also worth noting what the trial figures represent: weight-change percentages come from supervised studies with defined diet and follow-up, not from a guaranteed real-world outcome.

Notable compounds in this category

Semaglutide and Tirzepatide are the clinically established reference points; Retatrutide is the most-watched next-generation triple agonist; and AOD-9604 represents the older hGH-fragment approach. The GLP-1 revolution article in our blog traces how incretin science moved from research into medicine.

What to keep in mind

• Approval status varies sharply within this category; do not assume a compound is established because a neighbour is.
• Mechanism matters — incretin agonists, glucagon co-agonists and hGH fragments are not interchangeable.
• Trial weight-change figures reflect supervised study conditions, not a guaranteed outcome.
• This is the most clinically translated category on the site — its strongest evidence is genuinely strong.